Profound Medical Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year 2017; Provides Progress Update on TACT Pivotal Trial Patient Enrollment
For the full year 2017, the company anticipates total revenues to be approximately $4.9 million.
The company also reported that, as of December 31, 2017, the company-sponsored TACT pivotal clinical study, designed to further evaluate the safety and efficacy of TULSA-PRO® to ablate prostate tissue in patients with localized, organ-confined prostate cancer, had reached 87% (96 out of 110) patient enrollment. With an additional 14 patients still to be treated, Profound expects to complete study enrollment at some point during the month of February 2018.